4baseCare to focus on improved clinical outcomes and better quality of life for cancer patients

Yash Ved, MumbaiSaturday, September 11, 2021, 08:00 Hrs  [IST]

4baseCare, one of the leading precision oncology companies in India, is focusing on improved clinical outcomes and better quality of life for cancer patients.

The company is also aiming to leverage technology to build solutions that are affordable and accessible to patients.

The company stated that it is poised for growth and expansion across other Asian markets, while increasing digital capability. It added that it is also planning to raise US$ 2.2 million.

The company stated that it has collaborated with Wipro to develop precision oncology solutions that improves the affordability and timely availability of gene-testing reports for cancer patients.

4baseCare and Wipro jointly are paving the way for cancer patients to gain access to advanced genomic testing at an affordable cost and reduce the turnaround time (TAT) on the test results to almost half from the current market average of 30 days.

“Cancer is caused when our DNA/RNA is altered and the normal functioning of cells is not achieved. The alteration due to cancer leads the normal cell to follow a different path to proliferate, invade, and survive by dodging the immune-checkpoint mechanism. All the cancers reported till date are the outcome of mutations caused due to external or internal factors. Finding the root cause of genomic alteration that is associated with the types of cancer by next-generation sequencing helps the clinician to plan precise treatment,” stated Hitesh Goswami, co-founder and CEO of 4baseCare.

Goswami stated that lung cancer is one of the most well-researched types of cancer in terms of understanding the disease and targeted therapy options.

“Today, we have 12 approved biomarkers and associated therapies for its treatment. Hence, it is advisable to do a comprehensive genomic profiling by NGS at the time of diagnosis, as it will give us the complete insight on the genomic landscape of the disease. Doing so will also enable the clinician to take a personalized treatment approach in one go, leading to better treatment management and improved quality of life for the patients,” added Goswami.

4baseCare is the first company from Asia Pacific to be backed by global genomics leader Illumina through their Illumina Accelerator Programme. It develops affordable and accessible precision oncology solutions using genomics and digital health technology to personalize patient care in oncology.